SAN DIEGO, March 21 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that it is scheduled to present at the Lehman Brothers 2005 Global Healthcare Conference at the Loews Miami Beach Hotel in Miami, FL on Wednesday, March 30. Alexis V. Lukianov, Chairman and CEO, and Kevin C. O'Boyle, Executive Vice President and Chief Financial Officer of NuVasive, are scheduled to present on the Company's business at 9:30 a.m. ET.
A live Web cast and recording of the presentation will be available on NuVasive's Web site at http://www.nuvasive.com. The recording will be available until April 29, 2005.
NuVasive is a medical device company focusing on the design, development and marketing of products for use in minimally disruptive surgical treatments for the spine. NuVasive's Maximum Access Surgery (MAS(TM)) product platform includes the NeuroVision(R) nerve avoidance system, MaXcess(TM) spine access system, and specialized implants. NuVasive also offers classic fusion implant products for use in spine surgery and has an R&D pipeline emphasizing motion preservation products such as total disc replacement (TDR).
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to, the rapidly changing and competitive nature of the medical device industry, NuVasive's ability to convince surgeons to use its products, the ability of patients to obtain third-party reimbursement for surgical procedures employing NuVasive's products, risks related to government regulation of medical devices, risks related to NuVasive's ability to effectively manage the growth of its business, risks related to ownership and enforcement of intellectual property rights, NuVasive's ability to successfully develop new products, and other risks and uncertainties more fully described in NuVasive's Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission and NuVasive's Prospectus filed pursuant to Rule 424 under the Securities Act of 1933. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
SOURCE NuVasive, Inc.
Kevin C. O'Boyle, EVP & Chief Financial Officer of NuVasive, Inc., 858-909-1800, or firstname.lastname@example.org;
Investors: Stephanie Carrington, 646-536-7017, or email@example.com, or
Nick Laudico, 646-536-7030, or firstname.lastname@example.org, for NuVasive, Inc./
/Web site: http://www.nuvasive.com /
03/21/2005 09:00 EST http://www.prnewswire.com